PLoS ONE (Jan 2011)

Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection.

  • Amit Singhal,
  • El Moukhtar Aliouat,
  • Maxime Hervé,
  • Vanessa Mathys,
  • Mehdi Kiass,
  • Colette Creusy,
  • Baptiste Delaire,
  • Liana Tsenova,
  • Laurence Fleurisse,
  • Julie Bertout,
  • Luis Camacho,
  • Damian Foo,
  • Hui Chien Tay,
  • Jie Yee Siew,
  • Warda Boukhouchi,
  • Marta Romano,
  • Barun Mathema,
  • Véronique Dartois,
  • Gilla Kaplan,
  • Pablo Bifani

DOI
https://doi.org/10.1371/journal.pone.0018632
Journal volume & issue
Vol. 6, no. 4
p. e18632

Abstract

Read online

BACKGROUND: Despite the availability of many animal models for tuberculosis (TB) research, there still exists a need for better understanding of the quiescent stage of disease observed in many humans. Here, we explored the use of the Wistar rat model for the study of protective immunity and control of Mycobacterium tuberculosis (Mtb) infection. METHODOLOGY/PRINCIPAL FINDINGS: The kinetics of bacillary growth, evaluated by the colony stimulating assay (CFU) and the extent of lung pathology in Mtb infected Wistar rats were dependent on the virulence of the strains and the size of the infecting inoculums. Bacillary growth control was associated with induction of T helper type 1 (Th1) activation, the magnitude of which was also Mtb strain and dose dependent. Histopathology analysis of the infected lungs demonstrated the formation of well organized granulomas comprising epithelioid cells, multinucleated giant cells and foamy macrophages surrounded by large numbers of lymphocytes. The late stage subclinical form of disease was reactivated by immunosuppression leading to increased lung CFU. CONCLUSION: The Wistar rat is a valuable model for better understanding host-pathogen interactions that result in control of Mtb infection and potentially establishment of latent TB. These properties together with the ease of manipulation, relatively low cost and well established use of rats in toxicology and pharmacokinetic analyses make the rat a good animal model for TB drug discovery.